Search This Blog

Wednesday, February 22, 2023

Astellas Update on Recently Cleared Pompe Gene Therapy Trial

 After overcoming a clinical hold, Astellas presented preliminary safety and efficacy data from the Phase I/II FORTIS trial of AT845 in late-onset Pompe disease (LOPD) at the 19th Annual WORLDSymposium 2023.

Today, a diagnosis of Pompe disease ties people to twice-monthly infusions of enzyme replacement therapy (ERT). Astellas is trying to change that with AT845, a gene therapy that would serve as a one-time treatment for patients with LOPD.

As of September 15, 2022, four participants were treated with a one-time intravenous infusion of AT845. Two patients received 3x1013 vg/kg dose, while two were dosed at 6x1013 vg/kg.

At the data cut-off, three of the four participants were free of those ties to ERT. These individuals have shown continued stability in functional endpoints, including forced vital capacity and the 6-minute walk test, while off ERT for 19, 44 and 51 weeks, respectively.

Ahead of Wednesday’s presentation, Richard Wilson, senior vice president, primary focus lead – genetic regulation at Astellas, highlighted patient-reported fatigue outcomes as a critical data point. 

“We're really excited to see improvements in the…fatigue score, which is a really good quality of life measure,” he told BioSpace.

One participant, the first in the low-dose cohort, was unable to come off ERT. That patient has been moved to the higher-dose level, said Ha Tran, M.D., executive medical director, Astellas. 

Astellas has conducted a safety follow-up of up to 72 weeks in the staggered trial.

Pompe disease, also known as glycogen storage disease type II, is an autosomal recessive metabolic disorder that causes damage to muscle and nerve cells throughout the body. It is caused by mutations in the GAA gene; its job is to provide instructions for making acid alpha-glucosidase (GAA). This enzyme is responsible for breaking down glycogen.  

Glycogen is used for short-term energy storage and fuels much of the energy that powers muscle movements.

AT845 is an experimental adeno-associated virus (AAV) gene replacement therapy designed to deliver a functional copy of the GAA gene directly into the muscle cells of adult patients.  

Wilson said it is a fundamentally different way of delivering therapy in LOPD.

“We're delivering a gene to a patient's muscles where they're going to produce the enzyme that's needed in situ, whereas in ERT, you’re doing an IV infusion [and] relying on the diffusion of that enzyme to get into the muscle cells to see its benefit,” he said. 

Tran added that ERT could, over time, lead to some loss of efficacy and potentially immunogenic events.

Up and Running

The FDA placed the FORTIS study on clinical hold in June 2022 after one participant presented with peripheral sensory neuropathy. The hold was lifted in January 2023 after Astellas satisfied the regulator’s benefit-risk threshold, Ha said.

Next, the company intends to enroll an additional two participants in the study to gain a greater understanding of the safety and early efficacy signals.  

Ha said safety is top-of-mind.

“We’re really tightening up the inclusion criteria to ensure that any patients who are at risk for peripheral neuropathy would be excluded.” 

Wilson added that Astellas is “not seeing any signals of anything that looks out of the ordinary with any other kind of AVV gene therapy."

https://www.biospace.com/article/astellas-presents-update-on-recently-cleared-pompe-gene-therapy-trial-/

Stablecoins attract scrutiny in SEC’s drive to control crypto

 Washington’s battle to rein in crypto has a new front: stablecoins.

The Securities and Exchange Commission is investigating whether stablecoins, cryptocurrencies that maintain a price of $1, are among the products that were issued in violation of investor-protection laws. SEC enforcement lawyers have told Paxos Trust Co. that regulators plan to take enforcement action over its stablecoin, BUSD, although that decision isn’t final.

An SEC lawsuit over BUSD, the third-largest stablecoin by market value, would be a significant jolt to an industry that has suffered a series of shocks in recent weeks. After the failure of crypto exchange FTX, the SEC has already cut off the ability of some crypto middlemen to offer lending services that give crypto investors a way to earn interest by lending out their tokens.

After the collapse of FTX, Sam Bankman-Fried's cryptocurrency exchange, the SEC has been taking a much harder look at regulating the crypto world.

A lawsuit over stablecoins might not be easy for the SEC to win, according to securities lawyers, because stablecoin users don’t expect profits from owning the tokens. That motivation is one of the crucial prongs of a 1946 Supreme Court test, known as Howey, that regulators use to spot which cryptocurrencies are securities. 

"In your classic stablecoin…the profit is kept by the house," said Timothy Spangler, a partner at Dechert LLP who has advised clients on the structure and formation of products tied to digital assets. Even so, he added, "Regulators are well within their jurisdiction to look under the hood." 

Stablecoins are a form of cryptocurrency that make it easier to trade other digital assets. Each unit is supposed to maintain a value of $1. Traders can use stablecoins as a store of value, or use them to pay for other digital assets. Regulating them could take the SEC into the domain of overseeing payment products, something it doesn’t do.

Stablecoin issuers say they are backed 1-for-1 by cash or cash equivalents such as U.S. dollars and Treasury securities. Tether Holdings Ltd., the largest stablecoin issuer, discloses most of its portfolio holdings but not all. It has invested in riskier assets such as corporate debt and has made money by lending tethers to customers, a practice it is winding down. 

Tether briefly lost its $1 peg in May 2022, when it traded as low as 95 cents, reflecting factors including investors’ concerns at the time about the value of its assets and whether they could be readily sold to meet redemption requests in a market panic. 

Another possible complication for any SEC cases: The Commodity Futures Trading Commission and the New York State Department of Financial Services have labeled tether and BUSD as "virtual currencies." That doesn’t mean the SEC can’t allege they are securities, according to lawyers, but it muddies the waters and shows the difficulty of deciding which laws apply.  

Coinbase Global Inc. has disclosed the SEC is also investigating its stablecoin product. Coinbase maintains a partnership on the operation of USDC, the second-largest stablecoin, with Circle Internet Financial Ltd. Circle also has disclosed it faces an SEC investigation. A Circle spokesman declined to comment on the probe’s focus or status.

TickerSecurityLastChangeChange %
COINCOINBASE GLOBAL INC.61.18-0.89-1.43%

The SEC also could allege BUSD is a security through the application of another Supreme Court test that governs notes, or securities that promise the repayment of money, often with interest.

The SEC has cited that Supreme Court case, known as Reves, in other recent enforcement actions that found crypto lending programs operated by BlockFi Lending LLC and Nexo Capital Inc. should have been registered as securities. In those cases, the SEC said BlockFi’s and Nexo’s users were motivated by the ability to earn interest by lending out their crypto.

"We believe our stablecoins are unequivocally not securities under either Howey or Reves, and we look forward to continuing to work privately with federal regulators, including the SEC, to make this case," a Paxos spokeswoman said. 

Reves is a flexible test that can be applied to different scenarios. The Reves test considers the parties’ motivations but also asks whether another regulatory system applies to the asset, which would make SEC oversight unnecessary. New York financial regulators authorized the issuance of BUSD, and Paxos Trust is overseen by the state agency. 

"We think a court is going to look at that and say this is not the kind of situation where there is a vacuum to be filled," Coinbase Chief Legal Officer Paul Grewal said.

Stablecoins also don’t look too much like money-market funds, a comparison that SEC Chair Gary Gensler has made, Mr. Grewal and others said. Money funds promise to maintain a $1-a-share value but, unlike stablecoins, pay interest. 

The Securities and Exchange Commission is studying ways to make it more feasible for cryptocurrency trading platforms to register with the agency as exchanges, Chairman Gary Gensler said Monday Apr. 4th 2022 (Photo by Evelyn Hockstein-Pool/Getty Imag (Photo by Evelyn Hockstein-Pool/Getty Images / Getty Images)

The SEC’s money-fund rules haven’t always made those products as safe as investors expect. U.S. authorities had to prop up money funds in 2008 and 2020, when panicked investors stampeded out of some, creating the possibility of losses for slower-moving users. 

"Money-fund regulation is not really designed to support something that is supposed to be a payments instrument," said Jonah Crane, a partner at Klaros Group, a financial-services advisory firm. 

Other parts of the Biden administration have said stablecoins look more like banking products. The Treasury Department and U.S. financial regulators said in a November 2021 report that Congress should require stablecoin issuers to become banks. Congress hasn’t advanced such legislation. 

In the absence of congressional action, the Federal Reserve could assume oversight of stablecoins. But a multiagency panel of regulators would first need to designate stablecoin activities as a potential threat to the financial system. That hasn’t happened, either.

https://www.foxbusiness.com/money/stablecoins-attract-scrutiny-secs-drive-control-crypto

"You're Not Forgotten": Trump Speaks From East Palestine

 Update (1520ET):

Local TV station WKYC broadcasted Trump's speech in East Palestine. The former president said, "to the people of East Palestine and to the nearby communities of Ohio and Pennsylvania, we have told you loud and clear, 'you're not forgotten.'" 

Where is Biden?

*   *   * 

Update (1343ET):

Former President Trump has landed in East Palestine. 

Ahead of Trump's arrival, water and food are being passed out to residents. 

People of East Palestine aren't thrilled about the Biden administration, who've ignored the small town for weeks. 

Trump is expected to give a speech. 

*   *   * 

Former President Donald Trump is expected to visit East Palestine, Ohio, Wednesday and donate pallets of water and other supplies to the small town grappling with the toxic aftermath of the train derailment earlier this month. 

Last weekend we told readers about Trump's plan to visit East Palestine. Now it's been confirmed by Fox News that he will meet with officials and residents today.

Trump will meet with East Palestine Mayor Trent Conaway; Sen. J.D. Vance, R-Ohio; Rep. Bill Johnson, R-Ohio; State Rep. Monica Robb-Blasdel; and Ohio State Sen. Michael Rulli. 

"President Trump is meeting with the citizens of East Palestine and will never forget them and what they are going through.

"Contrast that with Biden and the federal government who has failed them from the beginning," a Trump advisor told Fox News.

On Monday, President Biden, who has barely mentioned East Palestine, decided to visit Ukraine instead of East Palestine. During an appearance on Fox News that same day, Mayor Trent Conaway said the president's visit overseas was the "biggest slap in the face" as his town continues to suffer following a freight train crash carrying hazardous materials, including vinyl chloride. 

"That was the biggest slap in the face that tells you right now, he doesn't care about us," Conaway told Fox's Jesse Watters. He added: "So … he can send every agency he wants to but I found that out this morning and one of the briefings that he was in the Ukraine giving millions of dollars away to people over there, not to us and I'm furious."


https://www.zerohedge.com/markets/trump-heads-east-palestine-capitalize-bidens-failed-toxic-train-derailment-response

Cerevel blames Covid for delayed neuroscience studies

 Neuroscience biotech Cerevel Therapeutics said data readouts for several clinical trials will come later than originally expected, and also disclosed the upcoming departure of its president, Abraham Ceesay.


The affected trials include a Phase II in focal epilepsy for darigabat, three Phase III trials for tavapadon in Parkinson’s and a Phase IIa of CVL-871 in dementia-related apathy. The epilepsy trial will read out sometime after 2023, the company said. Data had been expected in mid-2023. Another Phase II for darigabat will start next quarter in panic disorder.


Meanwhile, the three Phase III Parkinson’s trials will now read out in mid-year 2024 and the second half of 2024. Timelines for those trials have been impacted before, with the last quarterly update also including notes about “residual post-Covid landscape challenges.” The dementia-related apathy study is being delayed more than a year, from the first half of this year to the second half of 2024.



The delays are a blow to Cerevel, and the company’s stock $CERE slid 12% after the opening bell. The Pfizer spinout went public in 2020 via a combination with a blank check company.


Ceesay will leave on March 9 to fill the CEO role at an undisclosed private biotech, Cerevel said. Ceesay joined in 2021 after leading rare endocrine biotech Tiburio Therapeutics, which appears to have shuttered, per corporation filings. He did not immediately respond to an Endpoints News inquiry about his next post.



Cerevel did not cite any delays to readouts for its lead schizophrenia and Alzheimer’s disease psychosis drug candidate known as emraclidine. That’s going through two placebo-controlled Phase II trials and a 52-week open-label safety extension study in schizophrenia and a healthy volunteer study in people 65 to 85 years old for Alzheimer’s disease psychosis.


The biotech reeled in $573 million from a common stock and convertible note financing last August on the back of data from another schizophrenia drugmaker, Karuna Therapeutics, which reported a Phase III success.


Executives reiterated on an analyst call that the company has the financing to get through seven mid- to late-stage readouts in 2024, before its current runway expiration of 2025. The company had $950.2 million in cash, cash equivalents and marketable securities at the end of 2022.


CEO and chair Tony Coles declined to provide details of other biopharmas experiencing trial delays on the call, saying they don’t comment on other companies. Coles said his team pulled data from the federal trials database and said there are six- to 12-month delays “across the landscape, including in epilepsy,” but the impacts aren’t specific to neuroscience drugs. Coles cited residual Covid impacts and staffing shortages at sites as some factors for the trial struggles.

https://endpts.com/cerevel-blames-covid-for-delayed-neuroscience-studies-says-president-is-leaving/

AI-created images lose U.S. copyrights in test for new tech

 Images in a graphic novel that were created using the artificial-intelligence system Midjourney should not have been granted copyright protection, the U.S. Copyright Office said in a letter seen by Reuters.

"Zarya of the Dawn" author Kristina Kashtanova is entitled to a copyright for the parts of the book she wrote and arranged, but not for images she made using Midjourney, the office said in its letter, dated Tuesday.

The decision is one of the first by a U.S. court or agency on the scope of copyright protection for works created with AI, and comes amid the meteoric rise of generative AI software like Midjourney, Dall-E and ChatGPT.

The Copyright Office said in its letter that it would reissue its registration for "Zarya of the Dawn" to omit images that "are not the product of human authorship."

Midjourney did not immediately respond to a request for comment. The Copyright Office had no comment on the decision.

Kashtanova on Wednesday called it "great news" that she retained the copyright for her story and arrangement of the images, which she said "covers a lot of uses for the people in the AI art community."

She said she and her lawyers were considering how best to press ahead with their argument that the images themselves were a "direct expression of my creativity and therefore copyrightable."

Midjourney is an AI-based system that generates images based on text prompts entered by users. Kashtanova wrote the text of "Zarya of the Dawn," and Midjourney created the book's images based on her prompts.

The Copyright Office told Kashtanova in October it would reconsider the book's copyright registration because her application did not disclose Midjourney's role.

The office said on Tuesday that it would grant copyright protection for the book's text and the way Kashtanova selected and arranged its elements. But it said she was not the "master mind" behind the images themselves.

"The fact that Midjourney's specific output cannot be predicted by users makes Midjourney different for copyright purposes than other tools used by artists," the letter said. 

https://www.marketscreener.com/news/latest/AI-created-images-lose-U-S-copyrights-in-test-for-new-technology--43057108/

CDC panel recommends Bavarian Nordic's mpox vaccine for all adults at risk

 Advisers to the U.S. Centers for Disease Control and Prevention (CDC) on Wednesday voted in favor of use of Bavarian Nordic's Jynneos vaccine for all adults at risk of mpox during an outbreak.     

The recommendation of the committee is based on studies that showed vaccine effectiveness of 66%-83% for patients with full vaccination and 36%-86% for partial vaccination with no severe adverse affect.

The intradermal injection of Jynneos - that is between the layers of skin - is the preferred form of administration for adults during the outbreak, but is also approved as a subcutaneous injection, or below the skin.

The panel's recommendation will give Bavarian Nordic's vaccine an edge over Emergent BioSolutions' smallpox vaccine, which last year received approval for expanded use during mpox outbreak but its use has been largely limited owing to severe side-effects.

Mpox which spreads via close contact and tends to cause flu-like symptoms and pus-filled skin lesions, remains a public health emergency of international concern as World Health Organization earlier this month retained its highest level of alert for the disease citing continued transmission in some countries.

In the United States, more than 29,000 cases of mpox were reported last year, including two deaths, according to government data.

https://www.marketscreener.com/news/latest/CDC-panel-recommends-Bavarian-Nordic-s-mpox-vaccine-for-all-adults-at-risk--43057155/

Scientific Advances and Dietary Measures to Slow Down Aging

 Spectacular progress is being made in slowing down aging, with three new molecular indicators of measurable and manageable processes that accelerate or slow down deterioration associated with age, as well as age-related pathologies. These findings are closer than ever to being applied in older adults. Currently, diet is the most accessible form of intervention, but it is appropriate to clarify current myths and realities.

An article published in Cell in 2013 summarized for the first time the molecular indicators of aging in mammals. The article had a great impact and served as a knowledge map about aging. Now the authors have updated and extended this knowledge in the same journal.

A barometer of interest in the topic is that approximately 300,000 articles on aging have been published since 2013, which is as many as were published during the previous century. In addition, almost 80 experiments have been conducted with mammals, including humans, that confirm that interventions in the aging process can prevent, delay, and even avoid age-related diseases such as cancer.

María A. Blasco, MD, scientific director of the National Cancer Research Center, an international leader in telomere research and co-author of the study, noted on the institution's website, "The spectacular advances in recent years to increase the longevity of model organisms, including in mammals, indicate that it will be important to develop rational strategies to intervene in human aging."

Eighty Experimental Interventions

The new article verifies the conclusions of the analysis carried out a decade ago. "Now there is much more investment, and we are closer to applying basic knowledge to new ways of treating diseases," said Blasco. The researchers identified nine indicators of aging ― molecular signatures that mark the progress of the process and on which it was possible to act to prolong life.

They also point to four primary causes of aging: genomic instability, shortening of telomeres, epigenetic alterations, and imbalance between protein synthesis and degradation. These are strongly interconnected processes. Aging results from their joint action, which is why there are multiple ways to act on the physiologic process of aging. The new study includes a table with almost 80 recent experimental interventions with mammals (mostly mice) that suggest that it is possible to prolong life or treat age-associated diseases. Some of those studies concern humans; others investigate how to delay aging through diet. "Acting on the diet is one of the most accessible ways to intervene in human aging," according to the researchers.

Nutrient Sensors

Dietary interventions are related to a key indicator of aging: the dysregulation of the nutrient sensing mechanism. This mechanism is the sophisticated network of molecular signals that alert all mammals that food is available.

"Nutrient sensors are therapeutic targets for potential anti-longevity drugs, but health benefits and lifespan extension could also be achieved through dietary interventions. However, the results obtained in this line in our species are still unclear: clinical trials based on dietary restriction in humans become complicated due to poor compliance, although they suggest positive effects on immunity and inflammation," write the researchers.

Diet and Disease

Javier Gómez Pavón, MD, head of geriatrics at Red Cross Hospital in Madrid and member of the leadership team of the Spanish Society of Geriatrics and Gerontology, told Medscape Spanish Edition, "Currently, the evidence we have indicates that certain types of diet in population cohort studies are associated with a lower incidence and prevalence of certain diseases."

Gómez mentioned contrasting examples. "The Mediterranean diet has been shown in different studies to be associated with a lower cardiovascular risk (stroke, ischemic heart disease, dyslipidemia) and a lower risk of cognitive impairment, especially due to its vascular component."

Eating nuts (eg, almonds, walnuts) is associated with a less dyslipidemia. A diet rich in fiber is also associated with less colonic digestive pathology, such as constipation and especially colon cancer. In addition, a diet low in fatty meats and rich in fruits and vegetables is associated with less prostate, breast, and colon disease. A diet with adequate protein intake is related to better muscle mass at all ages, and a diet rich in calcium products, such as nuts and dairy products, is linked to better bone mass and less osteoporosis and its consequences.

"At the moment, there is no study that links any type of diet with greater longevity, although in view of these data, it seems logical that a Mediterranean diet rich in fruits, vegetables, vegetables with proteins of animal origin, preferably fish or white meat, avoiding excess red meat and its calcium component in the form of nuts and dairy products would be associated with better disease-free aging," said Gómez.

Aging Indicators

The article expands the aging indicators from nine to 12 (genomic instability, telomere wear, epigenetic alterations, loss of proteostasis, inactivated macroautophagy, dysregulation of nutrient sensing, mitochondrial dysfunction, cellular senescence, depletion of hematopoietic progenitor cells, alteration of intercellular communication, chronic inflammation and imbalances in the microbiome), which are measurable processes that change with the aging of the organism and which, when manipulated experimentally, induce an acceleration or, on the contrary, an interruption, even a regression, of aging.

"Each of these indicators should be considered an entry point for future exploration of the aging process, as well as for the development of new antiaging drugs," the researchers conclude.

A decade ago, it was recognized that telomere shortening was at the origin of age-related diseases, said Blasco. "It is now emphasized that the generation of mouse models with short telomeres has shown that telomeric wasting is at the origin of prevalent age-associated diseases, such as pulmonary and renal fibrosis."

The recent study reviews new interventions to delay aging and age-related diseases that act on telomeres. "For example, the activation of telomerase through a gene therapy strategy has shown therapeutic effects in mouse models of pulmonary fibrosis and aplastic anemia," Blasco added.

Food Fact and Fiction

Since diet is currently the most easily accessible element to slow down aging, Gómez refutes the most widespread myths that are circulating about food and longevity. First, regarding dairy products, it is said that yogurt is not useful for the elderly, since the elderly do not have adequate enzymes for to digest yogurt and that it is only for children or young people who are growing. "It is not true. Dairy products are not important for their proteins but for their calcium and vitamin D content. [These are] fundamental elements at all ages, but especially in aging, where there is bone loss secondary to aging itself and an increased risk of osteoporosis and associated fractures. Especially in the elderly, the tragic hip fracture is associated with high morbidity and mortality."

Another myth is that it is not good to eat fruit with meals. "Due to its rich content in antioxidants and vitamins, it is a fundamental food of the Mediterranean diet. Antioxidants of any type (nuts, vegetables, fruits, etc) are undoubtedly the most important components against pathological aging (stroke, myocardial infarction, dementia, etc). It may be true that they can be more easily digested if they are eaten outside of meals, but the important thing is that they be eaten whenever."

Sugars and Meat

"Regarding the 'fact' that the sugars in legumes and bread are harmful, it is not true. In addition to sugar, legumes contain fiber and other very important antioxidants, just like bread. The difference is the amount, as in all food. On the contrary, refined sugars, such as pastries, sugary drinks, etc, should be avoided, since they are directly related to cardiovascular disease and obesity," added Gómez.

"As for the popular saying, 'Do not even try meat,' it is not sound, since red meat and fish, including oily fish, are rich in protein and vitamin B as well as iron and, therefore, are necessary.

"As always, it is the amount that should be limited, especially red meat, not so much oily fish. I would recommend reducing red meat and replacing it with white meat, since the former are rich in saturated fats that produce more cholesterol," added Gómez.

Another phrase that circulates around is that wine is food. "Careful. Wine in small quantities, a glass at lunch and dinner, is beneficial due to its antioxidant power, but at more than these amounts, the negative power of alcohol predominates over its benefits," concluded Gómez.

Gómez has disclosed no relevant financial relationships.

https://www.medscape.com/viewarticle/988578